You are here
Outcomes of children exposed to chemotherapy in utero for breast cancer.
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).
Background: Increasing data are available regarding treating women diagnosed with breast cancer during pregnancy with chemotherapy in the second and third trimesters. Previous studies have demonstrated similar outcomes for pregnant and non-pregnant patients who receive standard therapies. However, there are limited data regarding potential health concerns for the children exposed to chemotherapy in utero. Methods: Between 1989-2010, 81 pts were treated with FAC during pregnancy in a prospective registry trial at our institution using a standardized chemotherapy regimen of 5-fluorouracil, doxorubin and cyclophosphamide (FAC) given during the second and third trimesters. Other standard systemic therapies were given after delivery. Outcomes of the women have been previously reported. Delivery records were obtained and IRB-approved health surveys sent to the parents or guardians of the children. Questions encompassed delivery, puberty and all health concerns. Results: Thus far, 41 of the surveys have been returned (51%). Median age of the children is 4 years (range <1-21 years). Mean weight at delivery was 3.09 kg (range 2.27 – 3.7 kg). Sixteen (39%) were delivered by c-section. During the delivery hospitalization 7 children (17%) required extra oxygen, 2 (4.8%) had hypoglycemia, and 2 (4.8%) had jaundice. Of the entire cohort (n=81) 1 child was born with Down’s syndrome, 1 with clubfoot and 1 with ureteral reflux (hydronephrosis). Three parents described some childhood language delay. There have been no reported significant delay in puberty and no children have had children of their own to date. Other reported health problems include 15 (36.6%) children with reports of allergies and/or eczema, 2 with asthma, 1 with arthritis-like symptoms, 1 with migraine headaches and 1 with a history of absence seizures. Survey data for the entire cohort will be updated at the time of presentation. Conclusions: Children exposed to chemotherapy in utero, overall appear to be doing well with no significant trend in increased medical problems, with the biggest long term health concern being allergies/eczema. Continued long-term follow-up of this and other cohorts is needed to provide more information to parents and pediatricians.
Abstracts by J. K. Litton:
Assessing the added value of breast tumor markers in breast cancer genetic risk prediction model BRCAPRO.Meeting: 2011 Breast Cancer Symposium | Abstract No: 164
Identifying genomic rearrangements in BRCA1 and BRCA2 in high-risk individuals for hereditary breast and ovarian cancer.Meeting: 2011 Breast Cancer Symposium | Abstract No: 163
- Meeting: 2011 ASCO Annual Meeting | Abstract No: 1106